Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NanoScan Imaging
Lansdale, PA, USAnanoscanimaging.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
NanoScan Imaging developed N1177, an investigational iodinated nanoparticulate contrast agent for CT imaging. Clinical and preclinical data demonstrated that N1177 is taken up by macrophages, enabling the visualization of vulnerable (high-risk) atherosclerotic plaques and the differentiation of cancerous from healthy lymph nodes. In late 2019, the company initiated a process to sell its physical inventory and intellectual property assets through a sealed-bid auction.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- NanoparticleSmall moleculeContrast agent
- Industry
- Medical Imaging
02
Partnerships
KodakSterling-WinthropNycomed-AmershamMount Sinai School of Medicine
Beyond the preview
Go deeper on NanoScan Imaging.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoScan Imaging.